scholarly journals Bone mineral metabolism and bone mineral density in alcohol related and idiopathic chronic pancreatitis

2014 ◽  
Vol 35 (2) ◽  
pp. 107-112 ◽  
Author(s):  
Anusree Prabhakaran
Keyword(s):  
Bone Mineral Density ◽  
Chronic Pancreatitis ◽  
Bone Mineral ◽  
Mineral Metabolism ◽  
Mineral Density ◽  
Bone Mineral Metabolism ◽  
Idiopathic Chronic Pancreatitis

Bone mineral metabolism, bone mineral density in patients with chronic pancreatitis

Pancreatology ◽  
2016 ◽  
Vol 16 (4) ◽  
pp. S107
Author(s):  
Ancuta Didita ◽  
Mihaela Dranga ◽  
Irina Ungureanu ◽  
Cristina Cijevschi Prelipcean ◽  
Catalina Mihai
Keyword(s):  
Bone Mineral Density ◽  
Chronic Pancreatitis ◽  
Bone Mineral ◽  
Mineral Metabolism ◽  
Mineral Density ◽  
Bone Mineral Metabolism

MO199DENOSUMAB: NOVEL APPROACH TO TREATMENT OF OSTEOPOROSIS IN RENAL DISEASE

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
Rosita Greco ◽  
Agata Mollica ◽  
Francesco Zincone ◽  
Teresa Papalia
Keyword(s):  
Bone Mineral Density ◽  
Renal Disease ◽  
Bone Mineral ◽  
Renal Allograft ◽  
Mineral Metabolism ◽  
Transplant Recipients ◽  
Mineral Density ◽  
Anca Vasculitis ◽  
T Score ◽  
Bone Mineral Metabolism

Abstract Background and Aims Denosumab is a fully human monoclonal antibody to the receptor activator of nuclear factor kappa-B ligand (RANKL), an osteoclast differentiating factor. It inhibits osteoclast formation, decrease bone resorption, increase bone mineral density (BMD), and reduce the risk of fracture. There is no restriction of its use in patients with renal disease, for whom biphosphonates are considered controindicated. The aim of our study was to evaluate the effectiveness in reducing facture risk and safety of Denosumab in patients with Osteoporosis and renal disease. Method This is a prospective analysis of 17 patients with Osteoporosis (average T-score below -2.5) admitted to our Nephrology Department for CKD in the last four years. in Vasculitis, Renal Allograft Recipients. Patients with severe Hyperparatiroidism were excluded. We estimated creatinine clearance (eGFR) using Cockcroft-Gault and classified levels of kidney function using the modified National Kidney Foundation classification of CKD. All patients were adequately supplemented with calcium and vitamin D before and while taking Denosumab 60 mg every 6 months. The primary endpoint is the change in bone mineral density (BMD) at one and two years. Secondary endpoints include changes in bone mineral metabolism parameters (Ca, P, PTHi, 25-OH VitD), incidence of fractures, and renal/allograft fuction at one and two years. Results The mean age was 52.5±4 years and 8/17 (47%) were females. N.13 patients (76.5%) were renal transplant recipients (RTR) on standard triple immunosoppression including steroids (prednisone 5 mg/day), CNI and MMF, with average eGFR 65.7±12.5 ml/min. N.2 patients (11.75%) were in hemodialysis. N.2 patients (11.75%) with Anca Vasculitis on steroid therapy and average eGFR 35.6±7.2 ml/min. All patients enrolled were with a BMD T-score of greater than -4.0 and less than -2.5. Only 2 patients had a history of fractures confirmed by a radiology report. Baseline parameters: calcium 9.8±0.32 mg/dl, phosphate 3.9±0.8 mg/dl, PTHi 137±91.0 ng/L, 25-OH VitD 18.3±8.9 ng/mL. From baseline at 1 month there were an increase in PTH and a decrease in calcemia in only 2 transplant recipients (CKD II and IV), that improved with an increased dose of Vit D. There were no significant difference in baseline bone mineral metabolism parameters to year 1 and 2 in all other patients. We found no difference in eGFR and proteinuria from baseline to 1 and 2 years in RTR and ANCA vasculitis. Significant improvement in T-score was observed at 1 year and 2 years (< -1) in all patients. No one discontinued therapy for adverse events. Conclusion Denosumab may have advantages in patients with kidney dysfunction, because not excreted by the kidney and there is no need for dose adjustment. This prospective study showed a significant improvement in osteoporosis (at Dexa mean T-score ≤ -1), but particular attention should be paid to ensuring that patients are calcium and Vitamin D replete.

224 Bone Mineral Metabolism in Patients With Alcohol Related and Idiopathic Chronic Pancreatitis

2012 ◽  
Vol 142 (5) ◽  
pp. S-55 ◽  
Author(s):  
Anusree Prabhakaran ◽  
Deepak K. Bhasin ◽  
Sanjay Bhadada ◽  
Niranjan Khandelwal ◽  
Anil Bhansali ◽  
...  
Keyword(s):  
Chronic Pancreatitis ◽  
Bone Mineral ◽  
Mineral Metabolism ◽  
Bone Mineral Metabolism ◽  
Idiopathic Chronic Pancreatitis

scholarly journals Bone mineral density in children with juvenile idiopathic arthritis after one year of treatment with etanercept

2018 ◽  
Vol 146 (5-6) ◽  
pp. 297-302
Author(s):  
Gordana Susic ◽  
Marija Atanaskovic ◽  
Roksanda Stojanovic ◽  
Goran Radunovic
Keyword(s):  
Bone Mineral Density ◽  
Juvenile Idiopathic Arthritis ◽  
Rheumatoid Factor ◽  
Bone Mineral ◽  
Mineral Metabolism ◽  
Z Score ◽  
Mineral Density ◽  
Bone Mineral Metabolism ◽  
Systemic Jia ◽  
One Year

Introduction/Objective. Juvenile idiopathic arthritis (JIA) is the most frequent chronic inflammatory, rheumatic disease of childhood, associated with disturbance of bone mineral metabolism, which develops gradually and progressively, and if untreated eventually leads to osteoporosis in adulthood. The aim of our study was to evaluate bone mineral density (BMD) in patients with JIA treated with etanercept over a period of one year. Methods. The prospective cohort study included 94 JIA patients (66 female, 28 male), their median age being 14.77 years. BMD was measured by dual-energy X-ray absorptiometry on the lumbar spine. Disease activity was assessed using the American College of Rheumatology Pedi 50 criteria. Results. After one year of treatment with etanercept, we found a statistically significant increment in all osteodensitometry variables (p < 0.001). Annual enhancement for the whole group was as follows: bone mineral content 15.8%, BMD 7.2%, BMDvol 4.2%. Z-score improved from -0.86 to -0.58 SD at the last visit, but decreased in rheumatoid factor-positive polyarthritis patients. Patients with systemic JIA had the lowest Z-score. Z-score correlated with functional disability level. BMD was lower in the group treated with glucocorticoids. Conclusion. Our results showed significant improvement of bone mineral density in children with JIA after one year of treatment with etanercept. Rheumatoid factor-positive and systemic JIA subtypes and treatment with glucocorticoids are the risk factors for impairing bone mineral metabolism.

Abstract #510 Mineral Metabolism and Bone Mineral Density in Patients with Neuroendocrine Tumors

2018 ◽  
Vol 24 ◽  
pp. 110-111
Author(s):  
Franco Grimaldi ◽  
Elda Kara ◽  
Fabio Vanin ◽  
Maria Carpentieri ◽  
Claudia Cipri ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Neuroendocrine Tumors ◽  
Bone Mineral ◽  
Mineral Metabolism ◽  
Mineral Density

Effects of dietary protein deficiency on mineral metabolism and bone mineral density

1992 ◽  
Vol 56 (2) ◽  
pp. 314-319 ◽  
Author(s):  
E Orwoll ◽  
M Ware ◽  
L Stribrska ◽  
D Bikle ◽  
T Sanchez ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Mineral ◽  
Dietary Protein ◽  
Mineral Metabolism ◽  
Protein Deficiency ◽  
Mineral Density
Sign in / Sign up

Export Citation Format

Share Document